Clinical Trial Update: A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

View source ↗

Summary

A Boehringer Ingelheim-sponsored European study assessing the safety of dabigatran in children under 2 with prior venous thromboembolism has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Dabigatran (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Status: WITHDRAWN